Corti Launches No-Equity Accelerator for Healthcare AI Startups

Why It Matters

By removing equity demands and supplying regulatory expertise, Corti speeds the entry of innovative AI solutions into tightly regulated health systems, expanding the pipeline of clinically validated products at a time when investors favor proven evidence.

Key Takeaways

• Corti's no-equity accelerator offers up to $5,000 in Symphony credits.
• Program provides regulatory support for EU AI Act and MDR compliance.
• EU MDR certification costs $218k‑$654k per device, taking 12‑18 months.
• Funding focus shifts to later-stage rounds favoring proven clinical evidence.
• OpenEvidence withdrew from Europe citing regulatory uncertainty under EU AI Act.

Pulse Analysis

The regulatory environment for medical artificial intelligence is tightening across the globe. In the United States, the FDA’s expanded AI/ML guidance demands continuous monitoring, while Canada and the United Kingdom have introduced lifecycle accountability rules. Europe, however, presents the steepest hurdle: the EU AI Act and the Medical Device Regulation (MDR) will classify most health‑AI tools as high‑risk, imposing certification costs of roughly $218,000 to $654,000 per device and timelines of 12 to 18 months. These barriers have already forced players like OpenEvidence, a $12 billion‑valued platform, to pull out of the European market.

Corti’s Startup Acceleration Program directly addresses that gap. By granting free access to its Symphony suite—an AI model that already serves over 100 million patients and has outperformed OpenAI on the HealthBench Professional benchmark—the company supplies the core clinical engine that most startups would otherwise need to build from scratch. The program adds up to $5,000 in credits across speech‑to‑text, coding and text‑generation services, and pairs founders with Corti’s regulatory and clinical teams. Crucially, the initiative requires no equity, allowing founders to retain ownership while navigating complex compliance pathways.

The timing aligns with a shift in capital toward later‑stage rounds that prioritize demonstrable clinical evidence and integrated workflows. By lowering the upfront cost of compliance and offering a proven AI foundation, Corti could catalyze a wave of niche, workflow‑specific solutions—especially in areas like psychiatric care where Aisel Health is already building on the platform. If successful, the accelerator may reshape the European health‑AI ecosystem, encouraging more startups to enter a market that was previously dominated by large, well‑funded players, and ultimately expanding the pool of AI‑driven clinical tools available to providers.